- Home
- UAN vs OCS Comparison
UAN vs OCS Comparison
Compare UAN & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAN
- OCS
- Stock Information
- Founded
- UAN 2007
- OCS 2003
- Country
- UAN United States
- OCS Switzerland
- Employees
- UAN N/A
- OCS N/A
- Industry
- UAN Agricultural Chemicals
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- UAN Industrials
- OCS Health Care
- Exchange
- UAN Nasdaq
- OCS Nasdaq
- Market Cap
- UAN 710.0M
- OCS 717.3M
- IPO Year
- UAN 2011
- OCS N/A
- Fundamental
- Price
- UAN $75.68
- OCS $17.31
- Analyst Decision
- UAN
- OCS Strong Buy
- Analyst Count
- UAN 0
- OCS 5
- Target Price
- UAN N/A
- OCS $29.20
- AVG Volume (30 Days)
- UAN 44.4K
- OCS 39.4K
- Earning Date
- UAN 10-28-2024
- OCS 11-07-2024
- Dividend Yield
- UAN 8.89%
- OCS N/A
- EPS Growth
- UAN N/A
- OCS N/A
- EPS
- UAN 4.97
- OCS N/A
- Revenue
- UAN $527,388,000.00
- OCS $1,027,571.00
- Revenue This Year
- UAN N/A
- OCS $6.87
- Revenue Next Year
- UAN N/A
- OCS $884.16
- P/E Ratio
- UAN $15.09
- OCS N/A
- Revenue Growth
- UAN N/A
- OCS N/A
- 52 Week Low
- UAN $61.62
- OCS $10.11
- 52 Week High
- UAN $88.94
- OCS $18.00
- Technical
- Relative Strength Index (RSI)
- UAN 53.84
- OCS 68.45
- Support Level
- UAN $74.25
- OCS $15.45
- Resistance Level
- UAN $77.62
- OCS $17.92
- Average True Range (ATR)
- UAN 2.18
- OCS 0.50
- MACD
- UAN -0.49
- OCS 0.17
- Stochastic Oscillator
- UAN 15.51
- OCS 81.42
About UAN CVR Partners LP Common Units representing Limited Partner Interests
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.